51
|
Hempel V, Heller W, Graf H. Parenterale Ernährung bei Polytrauma – Vergleich zwischen einem fettfreien und einem fetthaltigen Ernährungsregime. Transfus Med Hemother 2009. [DOI: 10.1159/000221200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
52
|
Albino CC, Paz-Filho G, Graf H. Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodarone-induced thyrotoxicosis (AIT). Clin Endocrinol (Oxf) 2009; 70:810-1. [PMID: 18771562 DOI: 10.1111/j.1365-2265.2008.03405.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
53
|
Cubas ER, Paz-Filho GJ, Olandoski M, Goedert CA, Woellner LC, Carvalho GA, Graf H. Recombinant human TSH increases the efficacy of a fixed activity of radioiodine for treatment of multinodular goitre. Int J Clin Pract 2009; 63:583-90. [PMID: 18803554 DOI: 10.1111/j.1742-1241.2008.01904.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
CONTEXT High doses of (131)I are usually needed in the treatment of multinodular goitre (MNG) for effective thyroid volume (TV) reduction. Recombinant human thyroid-stimulating hormone (rhTSH) is an adjuvant to enhance (131)I uptake, allowing a decrease in radiation activity and enhancing (131)I efficacy. OBJECTIVE To evaluate whether rhTSH increases the efficacy of a fixed activity of (131)I for the treatment of MNG. DESIGN Two-year, observational, placebo-controlled study. SETTING Patients received 0.1 mg rhTSH (A), 0.005 mg rhTSH (B) or placebo (C). A fixed activity of 1.11 GBq of (131)I was administered 24 h after rhTSH or placebo. PATIENTS A total of 28 outpatients (26 females and two males) with MNG. MEASUREMENTS TSH, free T4, T3, thyroglobulin (Tg) and TV. RESULTS Basal radioactive iodine uptake and TV values were comparable among all groups. After rhTSH or placebo, peak levels of TSH, free T4, T3 and Tg were higher in A than in B or in C (p < 0.05). Hyperthyroidism was observed in A (n = 2), B (n = 6) and C (n = 4). Thyroid enlargement was reported in A (n = 3) and B (n = 6). After 24 months, 10 patients developed hypothyroidism (four in A, three in B and three in C). TV reduction was similar between A and B (37.2 +/- 25.5% vs. 39.3 +/- 27.9%, p = 0.88), but different from the non-significant reduction in C (15.3 +/- 28.3%, p = 0.08). CONCLUSIONS Followed by 1.11 GBq, a very low dose of 0.005 mg rhTSH was equally safe and effective as 0.1 mg rhTSH. Both doses increased the efficacy of radioiodine. Adverse events were mild, transient and readily treatable.
Collapse
|
54
|
Thá Nassif A, Hintz Greca F, Graf H, Domingues Repka J, Nassif L. Wound Healing in Colonic Anastomosis in Hypothyroidism. Eur Surg Res 2009; 42:209-15. [DOI: 10.1159/000208519] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2008] [Accepted: 01/12/2009] [Indexed: 11/19/2022]
|
55
|
Hepp PG, Rack BK, Mouarrawy D, Groh U, Graf H, Göhler T, Finas D, Hönig A, Lichtenegger W, Sommer H, Janni W. CA 27.29 as a tumour marker for risk evaluation and therapy monitoring in patients with primary breast cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-2004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #2004
Background:
 Several trials show that the use of tumor markers leads to an early diagnosis of tumor dissemination in breast cancer patients. Whether this improves the prognosis is still under discussion. In the SUCCESS Trial CA27.29 has been examined before and after adjuvant chemotherapy (n=3754).
 Methods:
 The SUCCESS Trial compares FEC-Docetaxel (Doc) vs. FEC-Doc-Gemcitabine (Doc-G) regime and two vs. five year treatment with Zoledronat in patients with primary breast cancer (N+ or high risk). CA27.29 has been measured with ST AIA-PACK Ca27.29 reagent using MUC-1 for AIA-600II (Tosoh Bioscience, Tessenderlo, Belgium). The cutoff for positivity of CA27.29 is 24 U/ml.
 Results:
 2669 patients have been examined prospectively before and after chemotherapy. 22% of patients had a marker >24 U/ml (n=587, mean 19.00, range 3.04-410.00) before and 40% (n=1058, mean 23.34, range 2.70-330.76) after chemotherapy. The correlation between both values was significant (p<0.0005).
 While 17% showed elevated CA27.29 before and after therapy, 5% patients changed from positive to negative for CA27.29 afterwards. 55% were negative before and after therapy whereas 23% became positive after treatment.
 
 Before treatment the prevalence of elevated CA27.29 was equally distributed between the FEC-Doc and the FEC-Doc-G arm. After treatment 34.1% in the FEC-Doc arm showed an increased level vs. 45.6% in the FEC-Doc-G arm. The correlation analysis showed no significant coherence between hormonal status (ER: p<0.323; PR: p<0.078), HER2/neu status (p<0.308), Grading (p<0.565) and CA27.29 level. However, tumor size (p<0.020) and the nodal status (p<0.022) were significant associated with Ca27.29 levels.
 Conclusion:
 These results might indicate a close relation between Ca27.29 and tumour mass at primary diagnosis. Whether this marker will be useful for treatment monitoring will be shown by further follow-up in the Success-trial.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 2004.
Collapse
|
56
|
Kovarik J, Stummvoll H, Graf H, Müller M. Glucose Intolerance and Hemoglobin A, in Chronic Renal Insufficiency. Nephron Clin Pract 2008. [DOI: 10.1159/000182201] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
57
|
Haider DG, Fuhrmann H, Kovarik J, Heiss S, Graf H, Auinger M, Mittermayer F, Wolzt M, Hörl WH. Postprandial intradialytic dysglycaemia and diabetes in maintenance haemodialysis patients. Eur J Clin Invest 2008; 38:721-7. [PMID: 18837797 DOI: 10.1111/j.1365-2362.2008.02012.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Although the risk of developing dysglycaemia has been investigated in different communities this incidence is poorly studied in patients on maintenance haemodialysis (MHD). MATERIALS AND METHODS In a multicentre observational cohort study the occurrence of dysglycaemia was assessed in 239 primary normoglycaemic end stage renal disease (ERSD) patients on MHD. Dysglycaemia (fasting blood glucose > 110 mg dL(-1), > 140 mg dL(-1) 2 h after food intake) or diabetes (fasting blood glucose > 126 mg dL(-1) or > 200 mg dL(-1) at any time) were defined according to WHO criteria and cases were compared with age matched controls within the cohort. RESULTS Dysglycaemia was found in 82 primary normoglycaemic ESRD patients (34%) within 31 months after initiation of MHD. In 31 of these patients type 2 diabetes was diagnosed. When compared with matched control MHD patients differences in body mass index (BMI), HbA1c and postprandial blood glucose were detectable (P < 0.05). Increments in 0.1% of HbA1c were related with 11% higher odds for dysglycaemia (P = 0.002). In a subgroup of 36 primary normoglycaemic MHD patients who developed dysglycaemia event-free survival was 64%, 53%, 31%, 17% and 11% after 1, 2, 3, 4 and 5 years of haemodialysis treatment. CONCLUSION Onset of dysglycaemia or diabetes is frequent in ESRD patients after onset of chronic haemodialysis. Routine measurement of blood glucose before and after haemodialysis should be implemented as a standard of care during MHD.
Collapse
|
58
|
Paz-Filho GJ, Mesa CO, Carvalho GA, Goedert CA, Graf H. Recombinant human TSH associated with radioiodine does not have further effects on thyroid volume and function after 2 years. Clin Endocrinol (Oxf) 2008; 69:345-6. [PMID: 18167135 DOI: 10.1111/j.1365-2265.2007.03165.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
59
|
Paz-Filho G, Mesa-Junior C, Olandoski M, Woellner L, Goedert C, Boguszewski C, Carvalho G, Graf H. Effect of 30 mCi radioiodine on multinodular goiter previously treated with recombinant human thyroid-stimulating hormone. Braz J Med Biol Res 2007; 40:1661-70. [DOI: 10.1590/s0100-879x2006005000186] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2007] [Accepted: 08/27/2007] [Indexed: 11/22/2022] Open
|
60
|
Ruhrmann S, Salokangas R, Linzen D, Birchwood M, Juckel G, Schultze-Lutter F, Graf H, Reventlow V, Morrison A, Lewis S, Klosterkötter J. EPOS - sample characteristics, transition rates and psychopathological predictors. Eur Psychiatry 2007. [DOI: 10.1016/j.eurpsy.2007.01.247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
61
|
Boss A, Lichy MP, Martirosian P, Graf H, Claussen CD, Schlemmer HP, Schick F. High Resolution ASL Perfusion Imaging of the Kidneys at 3 Tesla. ROFO-FORTSCHR RONTG 2006. [DOI: 10.1055/s-2005-931838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
62
|
Boss A, Lichy MP, Martirosian P, Graf H, Claussen CD, Schlemmer HP, Schick F. High Resolution ASL Perfusion Imaging of the Kidneys at 3 Tesla. ROFO-FORTSCHR RONTG 2006. [DOI: 10.1055/s-2006-931869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
63
|
Schick F, Pintaske J, Martirosian P, Graf H, Erb G, Lodemann KP, Claussen C. CMR 2005: 13.03: Relaxivity of gadopentetate dimeglumine, gadobutrol and gadobenate dimeglumine in human blood plasma at 0.2, 1.5 and 3 T. CONTRAST MEDIA & MOLECULAR IMAGING 2006. [DOI: 10.1002/cmmi.75] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
64
|
Lauer UA, Graf H, Dautel H, Claussen CD, Schick F. HF-induzierte Artefakte bei 3 Tesla: Positionierung einer elektrisch leitfähigen Probe im Magneten und die Geometrie des umgebenden Mediums als relevante Einflussgrößen. ROFO-FORTSCHR RONTG 2006. [DOI: 10.1055/s-2006-941060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
65
|
Schraml CB, Aubé C, Graf H, Boss A, Clasen S, Herberts T, Schick F, Claussen CD, Pereira PL. MR-gesteuerte Radiofrequenzablation: Beeinflusst das statische Magnetfeld Form und Volumen der Koagulationsnekrose? ROFO-FORTSCHR RONTG 2006. [DOI: 10.1055/s-2006-941100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
66
|
Boss A, Martirosian P, Graf H, Claussen CD, Schlemmer HP, Schick F. High Resolution MR Perfusion Imaging of the Kidneys at 3 Tesla without Administration of Contrast Media. ROFO-FORTSCHR RONTG 2005; 177:1625-30. [PMID: 16333784 DOI: 10.1055/s-2005-858761] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
PURPOSE The feasibility of high-resolution arterial spin labeling (ASL) perfusion imaging of the kidneys was tested and proven at 3 Tesla using a flow-sensitive alternating inversion recovery (FAIR) true fast imaging in steady precession (TrueFISP) technique. MATERIALS AND METHODS Kidney perfusion maps of six healthy volunteers and two patients were acquired using a clinical 3-Tesla whole-body scanner. An ASL sequence with FAIR spin preparation and a TrueFISP signal detection strategy was adapted for high-resolution perfusion imaging of the kidneys at 3 Tesla. To avoid banding artifacts in TrueFISP images, which are generally prominent at 3 Tesla, a frequency scout was implemented. Perfusion maps with an in-plane resolution of 1.5 mm were recorded in transverse and coronal orientation. For fast mapping of whole-kidney perfusion, an in-plane resolution of 2 mm was applied. RESULTS In all volunteers and patients, high-resolution perfusion images with excellent image quality were able to be obtained in a measuring time of approximately 10 minutes. The whole kidney was able to be mapped with good image quality in less than 10 minutes. For all slices, a suitable frequency offset made it possible to reproduce the kidneys without TrueFISP artifacts. Perfusion values of the renal cortex ranged from 250 ml/100 g/min up to 400 ml/100 g/min (mean cortical perfusion right kidney 316 +/- 43, left 336 +/- 40). CONCLUSION High-resolution ASL perfusion images of the whole kidney were able to be obtained with good image quality by means of a 3 Tesla MR setting within a clinically applicable measuring time, thus providing an alternative to conventional perfusion imaging involving potentially nephrotoxic contrast media.
Collapse
|
67
|
Graf H. FEBS meeting 1998, July 5-10, Kopenhagen. Expert Opin Investig Drugs 2005; 7:1559-60. [PMID: 15992052 DOI: 10.1517/13543784.7.9.1559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
68
|
Boss A, Martirosian P, Graf H, Schäfer J, Schick F. Perfusionsbildgebung der Lungen mit Arterial-Spin-Labeling. ROFO-FORTSCHR RONTG 2005. [DOI: 10.1055/s-2005-867654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
69
|
Boss A, Graf H, Müller-Bierl B, Clasen S, Schmidt D, Pereira P, Schick F. Einfluss der RF-Applikatorverschiebung auf das Temperaturmonitoring mit der Protonen-Resonanz-Frequenz-Methode. ROFO-FORTSCHR RONTG 2005. [DOI: 10.1055/s-2005-868297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
70
|
Lauer UA, Graf H, Claussen CD, Schick F. MRT-Artefakte bei Verbundwerkstoffen bis 3.0 Tesla. ROFO-FORTSCHR RONTG 2005. [DOI: 10.1055/s-2005-868346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
71
|
Pintaske JP, Martirosian P, Graf H, Erb G, Lodemann KP, Schick F, Claussen CD. Vergleich konzentrationsabhängiger Relaxivitäten von Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist) und Gadobenate Dimeglumine (MultiHance) im Blutplasma bei 0.2T, 1.5T und 3T. ROFO-FORTSCHR RONTG 2005. [DOI: 10.1055/s-2005-867725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
72
|
Albino CC, Mesa CO, Olandoski M, Ueda CE, Woellner LC, Goedert CA, Souza AM, Graf H. Recombinant human thyrotropin as adjuvant in the treatment of multinodular goiters with radioiodine. J Clin Endocrinol Metab 2005; 90:2775-80. [PMID: 15713700 DOI: 10.1210/jc.2004-0458] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The use of 131I in the treatment of multinodular goiters (MNG) is well established. We evaluated the effect of 30 microCi 131I (1.11 GBq) in 18 patients with MNG with the aid of two injections of 0.1 mg recombinant human TSH (rhTSH), given on d 1 and 2. A dose of 30 microCi 131I was given on d 3. TSH, T3, free T4, and thyroglobulin were measured on d 1, 2, 3, 5, 10, 30, 60, 90, and 180, and antithyroid antibodies were measured on d 1, 30, 90, and 180. Twenty-four-hour 131I uptake measured 1-3 months before rhTSH increased from 12.3 +/- 6.2 to 53.5 +/- 10.9% (P < 0.0001), free T4 from 1.3 +/- 0.2 to peak 3.2 +/- 1.1 ng/dl levels (P < 0.0001), T3 from 113.9 +/- 35.0 to peak 332.2 +/- 123.0 ng/dl levels (P < 0.0001), TSH from 0.76 +/- 0.71 to peak 18.9 +/- 5. 3 mU/liter levels (P < 0.0001), and thyroglobulin from 280.9 +/- 370.0 to peak 1838.5 +/- 1360.7 ng/dl levels (P = 0.001). Painful thyroiditis (33%) and mild thyrotoxicosis (39%) constituted minor side effects. There were no changes in echocardiographic parameters, done before and after rhTSH administration, on d 3. Hypothyroidism developed in 65%. Mean goiter size, measured by computed tomography, decreased from 97.9 +/- 45.4 to 65.5 +/- 47.3 ml (P < 0.0001; reduction: 39 +/- 19%) after 6 months. We conclude that rhTSH is a safe and efficient therapeutic tool in the treatment of MNG allowing the use of outpatient therapeutic 131I doses.
Collapse
|
73
|
Schraml CS, Graf H, Boss A, Clasen S, Claussen CD, Pereira P, Schick F. Beeinflussung des MR-Bildes durch Neutralelektroden bei der Radiofrequenzablation: Artefaktanalyse und -reduktion bei 0,2 und 1.5 Tesla. ROFO-FORTSCHR RONTG 2005. [DOI: 10.1055/s-2005-868307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
74
|
Müller-Bierl B, Graf H, Schick F, Claussen CD. Optimierung von Nadelspitzenartefakten durch kombinierten Einsatz von para- mit diamagnetischen Materialien: Eine numerische Studie. ROFO-FORTSCHR RONTG 2005. [DOI: 10.1055/s-2005-868375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
75
|
Graf H, Steidle G, Lauer UA, Claussen CD, Schick F. Radiofrequenz-Abschirmung des Lumens metallischer Stents in der MRA. ROFO-FORTSCHR RONTG 2005. [DOI: 10.1055/s-2005-867926] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|